Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00232024 · ClinicalTrials.gov registry record · Phase 3
Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,296
- Enrollment target
NCT00232024 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 1,296 participants.
The verdict
NCT00232024, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,296 participants
- Enrollment target
Study Summary
This study is being done to evaluate the safety, tolerability and satisfactory relief of dyspepsia symptoms in females excluding those with predominant stomach pain. Tegaserod will be evaluated at 6mg twice daily and placebo.
Interventions
- DRUG Tegaserod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,296 participants |
| Start Date | 2004-01 |
| Est. Completion | 2006-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00232024
The ClinicalTrials.gov registry entry for NCT00232024 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,296 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tegaserod is the first listed.
NCT00232024 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00232024 about?
NCT00232024 is a clinical study titled "Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia". This study is being done to evaluate the safety, tolerability and satisfactory relief of dyspepsia symptoms in females excluding those with predominant stomach pain. Tegaserod will be evaluated at 6mg twice daily and placebo.
What is the current status of trial NCT00232024?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,296 participants. The study started on 2004-01. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00232024?
The interventions under investigation include: Tegaserod (DRUG).
Who is sponsoring clinical trial NCT00232024?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.